{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:40:24Z","timestamp":1790700024782,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cryptogenic stroke is a heterogeneous condition, with a wide spectrum of possible underlying causes for which the optimal secondary prevention may differ substantially. Attempting a correct etiological diagnosis to reduce the stroke recurrence should be the fundamental goal of modern stroke management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective observational international multicenter study of cryptogenic stroke and cryptogenic transient ischemic attack (TIA) patients clinically monitored for 12 months to assign the underlying etiology. For atrial fibrillation (AF) detection continuous cardiac rhythm monitoring with insertable cardiac monitor (Reveal LINQ, Medtronic) was performed. The 12-month follow-up data for 250 of 259 initially included NOR-FIB patients were available for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 12 months follow-up probable stroke causes were revealed in 43% patients, while 57% still remained cryptogenic. AF and atrial flutter was most prevalent (29%). In 14% patients other possible causes were revealed (small vessel disease, large-artery atherosclerosis, hypercoagulable states, other cardioembolism). Patients remaining cryptogenic were younger (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), had lower CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASc score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) on admission, and lower NIHSS score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031) and mRS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016) at discharge. Smoking was more prevalent in patients that were still cryptogenic (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014), while dyslipidaemia was less prevalent (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044). Stroke recurrence rate was higher in the cryptogenic group compared to the group where the etiology was revealed, 7.7% vs. 2.8%, (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.091).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Cryptogenic stroke often indicates the inability to identify the cause in the acute phase and should be considered as a\n                      <jats:italic>working<\/jats:italic>\n                      diagnosis until efforts of diagnostic work up succeed in identifying a specific underlying etiology. Timeframe of 6-12-month follow-up may be considered as optimal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier NCT02937077, EudraCT 2018-002298-23.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03155-0","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:03:06Z","timestamp":1679385786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Underlying causes of cryptogenic stroke and TIA in The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study \u2013 the importance of comprehensive clinical evaluation"],"prefix":"10.1186","volume":"23","author":[{"given":"B.","family":"Ratajczak-Tretel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Tancin","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Al-Ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Arntzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. K.","family":"Bakkejord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.O.","family":"Bekkeseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bjerkeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Eld\u00f8en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Gulsvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A.","family":"H\u00f8ie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ihle-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ingebrigtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. B.","family":"Krogseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kruuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nakstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Novotny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Naess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Rezaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"R\u00f8rholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. H.","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"S\u00f8mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tobro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. C.","family":"Truelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wassvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"\u00c6gidius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Atar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Aamodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"3155_CR1","doi-asserted-by":"publisher","unstructured":"Saini V, Guada L, Yavagal DR. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions.Neurology. 2021 Nov16;97(20 Suppl 2):S6-S16. doi: https:\/\/doi.org\/10.1212\/WNL.0000000000012781.","DOI":"10.1212\/WNL.0000000000012781"},{"key":"3155_CR2","doi-asserted-by":"publisher","unstructured":"Chen PH, Gao S, Wang YJ et al. Classifying Ischemic Stroke, from TOAST to CISS. CNS Neurosci Ther. 2012 Jun;18(6):452\u20136. doi: https:\/\/doi.org\/10.1111\/j.1755-5949.2011.00292.x.","DOI":"10.1111\/j.1755-5949.2011.00292.x"},{"key":"3155_CR3","doi-asserted-by":"publisher","unstructured":"Liberman AL, Prabhakaran S. Cryptogenic stroke: how to define it? How to treat it? Curr Cardiol Rep. 2013 Dec;15(12):423. doi: https:\/\/doi.org\/10.1007\/s11886-013-0423-x.","DOI":"10.1007\/s11886-013-0423-x"},{"key":"3155_CR4","doi-asserted-by":"publisher","unstructured":"Saver JL, CLINICAL PRACTICE, Cryptogenic Stroke N, Engl JM. 2016 May 26;374(21):2065\u201374. doi: https:\/\/doi.org\/10.1056\/NEJMcp1503946.","DOI":"10.1056\/NEJMcp1503946"},{"key":"3155_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCRESAHA.116.308447","volume":"120","author":"S Yaghi","year":"2017","unstructured":"Yaghi S, Bernstein RA, Passman R, et al. Cryptogenic stroke: research and practice. Circ Res. 2017;120:527\u201340. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308447.","journal-title":"Circ Res"},{"key":"3155_CR6","doi-asserted-by":"publisher","unstructured":"Hart RG, Diener HC, Coutts SB, Cryptogenic Stroke\/ESUS International Working Group, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014 Apr;13(4):429\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(13)70310-7.","DOI":"10.1016\/S1474-4422(13)70310-7"},{"key":"3155_CR7","doi-asserted-by":"publisher","unstructured":"Diener HC, Bernstein R, Hart R. Secondary Stroke Prevention in Cryptogenic Stroke and Embolic Stroke of undetermined source (ESUS). Curr Neurol Neurosci Rep. 2017 Sep;17(9):64. https:\/\/doi.org\/10.1007\/s11910-017-0775-5.","DOI":"10.1007\/s11910-017-0775-5"},{"key":"3155_CR8","doi-asserted-by":"publisher","unstructured":"Bang OY, Ovbiagele B, Kim JS. Evaluation of cryptogenic stroke with advanced diagnostic techniques. Stroke. 2014 Apr;45(4):1186\u201394. https:\/\/doi.org\/10.1161\/STROKEAHA.113.003720.","DOI":"10.1161\/STROKEAHA.113.003720"},{"key":"3155_CR9","doi-asserted-by":"publisher","unstructured":"Diener HC, Sacco RL, Easton JD, et al. RE-SPECT ESUS Steering Committee and investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of undetermined source. N Engl J Med. 2019 May;16(20):1906\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1813959.","DOI":"10.1056\/NEJMoa1813959"},{"key":"3155_CR10","doi-asserted-by":"publisher","unstructured":"Hart RG, Sharma M, Mundl H et al. NAVIGATE ESUS Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun7;378(23):2191\u20132201. doi: https:\/\/doi.org\/10.1056\/NEJMoa1802686.","DOI":"10.1056\/NEJMoa1802686"},{"issue":"3","key":"3155_CR11","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873221100032","volume":"7","author":"J Dawson","year":"2022","unstructured":"Dawson J, B\u00e9jot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022;7(3):I\u2013II. https:\/\/doi.org\/10.1177\/23969873221100032.","journal-title":"Eur Stroke J"},{"key":"3155_CR12","doi-asserted-by":"publisher","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi: https:\/\/doi.org\/10.1161\/STR.0000000000000375.","DOI":"10.1161\/STR.0000000000000375"},{"key":"3155_CR13","doi-asserted-by":"publisher","unstructured":"Ratajczak-Tretel B, Lambert AT, Johansen H, et al. Atrial fibrillation in cryptogenic stroke and transient ischaemic attack - the nordic Atrial Fibrillation and Stroke (NOR-FIB) study: Rationale and design. Eur Stroke J. 2019 Jun;4(2):172\u201380. https:\/\/doi.org\/10.1177\/2396987319837089.","DOI":"10.1177\/2396987319837089"},{"issue":"1","key":"3155_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000504529","volume":"10","author":"A Tancin Lambert","year":"2020","unstructured":"Tancin Lambert A, Kong XY, Ratajczak-Tretel B, et al. Biomarkers Associated with Atrial Fibrillation in patients with ischemic stroke: a pilot study from the NOR-FIB Study. Cerebrovasc Dis Extra. 2020;10(1):11\u201320. https:\/\/doi.org\/10.1159\/000504529.","journal-title":"Cerebrovasc Dis Extra"},{"key":"3155_CR15","doi-asserted-by":"publisher","unstructured":"Ratajczak-Tretel B, Tancin Lambert A, Al-Ani R, et al. Atrial fibrillation in cryptogenic stroke and TIA patients in the nordic Atrial Fibrillation and Stroke (NOR-FIB) study: main results. Eur Stroke J. 2022;0(0). https:\/\/doi.org\/10.1177\/23969873221123122.","DOI":"10.1177\/23969873221123122"},{"key":"3155_CR16","doi-asserted-by":"publisher","unstructured":"Lang RM, Bierig M, Devereux RB, American Society of Echocardiography\u2019s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association, et al. European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006 Mar;7(2):79\u2013108. https:\/\/doi.org\/10.1016\/j.euje.2005.12.014.","DOI":"10.1016\/j.euje.2005.12.014"},{"key":"3155_CR17","doi-asserted-by":"publisher","unstructured":"Lang RM, Badano LP, Mor-Avi V. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1\u201339e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003.","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"3155_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1586\/17434440.2014.953059","volume":"12","author":"TT Tomson","year":"2015","unstructured":"Tomson TT, Passman R. The reveal LINQ insertable cardiac monitor. Expert Rev Med Devices. 2015;12:7\u201318. https:\/\/doi.org\/10.1586\/17434440.2014.953059.","journal-title":"Expert Rev Med Devices"},{"key":"3155_CR19","doi-asserted-by":"publisher","unstructured":"Tsivgoulis G, Triantafyllou S, Palaiodimou L et al. Prolonged Cardiac Monitoring and Stroke Recurrence: A Meta-analysis. Neurology. 2022 May 10;98(19):e1942-e1952. doi: https:\/\/doi.org\/10.1212\/WNL.0000000000200227.","DOI":"10.1212\/WNL.0000000000200227"},{"key":"3155_CR20","doi-asserted-by":"publisher","unstructured":"Lu Y, Diao SS, Huang SJ, et al. Insertable cardiac monitors for detection of atrial fibrillation after cryptogenic stroke: a meta-analysis. Neurol Sci. 2021 Oct;42(10):4139\u201348. https:\/\/doi.org\/10.1007\/s10072-021-05104-6.","DOI":"10.1007\/s10072-021-05104-6"},{"key":"3155_CR21","doi-asserted-by":"publisher","unstructured":"Hindricks G, Potpara T, Dagres N, ESC Scientific Document Group., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, Eur Heart J, Volume\u00a042, Issue 5, 1 February 2021, Pages 373\u2013498. doi: https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"3155_CR22","doi-asserted-by":"publisher","unstructured":"Lindsay P, Furie KL, Davis SM, et al. World Stroke Organization global stroke services guidelines and action plan. Int J Stroke. 2014 Oct;9(Suppl A):4\u201313. https:\/\/doi.org\/10.1111\/ijs.12371.","DOI":"10.1111\/ijs.12371"},{"key":"3155_CR23","doi-asserted-by":"publisher","unstructured":"Norrving B, Barrick J, Davalos A, et al. Action Plan for Stroke in Europe 2018\u20132030. Eur Stroke J. 2018 Dec;3(4):309\u201336. https:\/\/doi.org\/10.1177\/2396987318808719.","DOI":"10.1177\/2396987318808719"},{"key":"3155_CR24","doi-asserted-by":"publisher","unstructured":"Rubiera M, Aires A, Antonenko K et al. European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. Eur Stroke J. 2022Sep;7(3):VI. doi: https:\/\/doi.org\/10.1177\/23969873221099478.","DOI":"10.1177\/23969873221099478"},{"key":"3155_CR25","doi-asserted-by":"publisher","unstructured":"Yang H, Nassif M, Khairy P et al. Cardiac diagnostic work-up of ischaemic stroke. Eur Heart J. 2018 May 21;39(20):1851\u20131860. doi: https:\/\/doi.org\/10.1093\/eurheartj\/ehy043.","DOI":"10.1093\/eurheartj\/ehy043"},{"key":"3155_CR26","doi-asserted-by":"publisher","unstructured":"Bulwa Z, Gupta A. Embolic stroke of undetermined source: The role of the nonstenotic carotid plaque.J Neurol Sci. 2017 Nov15;382:49\u201352. doi: https:\/\/doi.org\/10.1016\/j.jns.2017.09.027.","DOI":"10.1016\/j.jns.2017.09.027"},{"key":"3155_CR27","doi-asserted-by":"publisher","unstructured":"Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005 Nov;58(5):688 \u2013 97. doi: https:\/\/doi.org\/10.1002\/ana.20617. PMID: 16240340.","DOI":"10.1002\/ana.20617"},{"key":"3155_CR28","doi-asserted-by":"publisher","unstructured":"Cannistraro RJ, Badi M, Eidelman BH, et al. CNS small vessel disease: a clinical review. Neurology. 2019 Jun;11(24):1146\u201356. https:\/\/doi.org\/10.1212\/WNL.0000000000007654.","DOI":"10.1212\/WNL.0000000000007654"},{"key":"3155_CR29","doi-asserted-by":"publisher","unstructured":"Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019 Jul;18(7):684\u201396. https:\/\/doi.org\/10.1016\/S1474-4422(19)30079-1.","DOI":"10.1016\/S1474-4422(19)30079-1"},{"key":"3155_CR30","doi-asserted-by":"publisher","unstructured":"Salehi Omran S, Hartman A, Zakai NA, Navi BB. Thrombophilia Testing After Ischemic Stroke: Why, When, and What? Stroke. 2021 May;52(5):1874\u20131884. doi: https:\/\/doi.org\/10.1161\/STROKEAHA.120.032360.","DOI":"10.1161\/STROKEAHA.120.032360"},{"key":"3155_CR31","doi-asserted-by":"publisher","unstructured":"Zhang S, Zhang J, Wang C, Chen X, Zhao X, Jing H, Liu H, Li Z, Wang L, Shi J. COVID-19 and ischemic stroke: mechanisms of hypercoagulability (review). Int J Mol Med. 2021 Mar;47(3):21. https:\/\/doi.org\/10.3892\/ijmm.2021.4854.","DOI":"10.3892\/ijmm.2021.4854"},{"key":"3155_CR32","doi-asserted-by":"publisher","unstructured":"Dardiotis E, Aloizou AM, Markoula S, et al. Cancer-associated stroke: pathophysiology, detection and management (review). Int J Oncol. 2019 Mar;54(3):779\u201396. https:\/\/doi.org\/10.3892\/ijo.2019.4669.","DOI":"10.3892\/ijo.2019.4669"},{"key":"3155_CR33","doi-asserted-by":"publisher","unstructured":"Salazar-Camelo RA, Moreno-Vargas EA, Cardona AF, Bayona-Ortiz HF. Ischemic stroke: a paradoxical manifestation of cancer. Crit Rev Oncol Hematol. 2021 Jan;157:103181. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103181.","DOI":"10.1016\/j.critrevonc.2020.103181"},{"key":"3155_CR34","doi-asserted-by":"publisher","unstructured":"Navi BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and Embolic Stroke of undetermined source. Stroke. 2021 Mar;52(3):1121\u201330. https:\/\/doi.org\/10.1161\/STROKEAHA.120.032002.","DOI":"10.1161\/STROKEAHA.120.032002"},{"key":"3155_CR35","doi-asserted-by":"crossref","unstructured":"Zhang F, Wang K, Du P et al. Risk of Stroke in Cancer Survivors: A Meta-analysis of Population-Based Cohort Studies.Neurology. 2021 Jan26;96(4):e513-e526.","DOI":"10.1212\/WNL.0000000000011264"},{"key":"3155_CR36","doi-asserted-by":"publisher","unstructured":"Ntaios G, Papavasileiou V, Milionis H et al. Embolic strokes of undetermined source in the Athens stroke registry: a descriptive analysis.Stroke. 2015Jan;46(1):176\u201381. doi: https:\/\/doi.org\/10.1161\/STROKEAHA.114.007240.","DOI":"10.1161\/STROKEAHA.114.007240"},{"key":"3155_CR37","doi-asserted-by":"publisher","unstructured":"Mele F, Scopelliti G, Manini A et al. Etiologic reclassification of cryptogenic stroke after implantable cardiac monitoring and computed tomography angiography re-assessment.J Neurol. 2022 Sep13:1\u20139. doi: https:\/\/doi.org\/10.1007\/s00415-022-11370-x.","DOI":"10.1007\/s00415-022-11370-x"},{"key":"3155_CR38","doi-asserted-by":"publisher","unstructured":"Mohr JP. Cryptogenic stroke., Engl N. J Med. 1988 May 5;318(18):1197-8. doi: https:\/\/doi.org\/10.1056\/NEJM198805053181810.","DOI":"10.1056\/NEJM198805053181810"},{"key":"3155_CR39","doi-asserted-by":"publisher","unstructured":"Li L, Yiin GS, Geraghty OC, et al. Oxford Vascular Study. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015 Sep;14(9):903\u201313. https:\/\/doi.org\/10.1016\/S1474-4422(15)00132-5.","DOI":"10.1016\/S1474-4422(15)00132-5"},{"key":"3155_CR40","doi-asserted-by":"crossref","unstructured":"Andreasen C, Gislason GH, K\u00f8ber L, et al. Incidence of ischemic stroke in individuals with and without aortic valve stenosis: a danish Retrospective Cohort Study. Stroke. 2020 May;51(5):1364\u201371.","DOI":"10.1161\/STROKEAHA.119.028389"},{"key":"3155_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11936-019-0786-4","volume":"21","author":"B Mac Grory","year":"2019","unstructured":"Mac Grory B, Flood S, Apostolidou E, et al. Cryptogenic stroke: diagnostic workup and management. Curr Treat Options Cardio Med. 2019;21:77. https:\/\/doi.org\/10.1007\/s11936-019-0786-4.","journal-title":"Curr Treat Options Cardio Med"},{"key":"3155_CR42","doi-asserted-by":"crossref","unstructured":"Ratajczak-Tretel B, Lambert AT, Atar D, Aamodt AH. Cryptogenic stroke and TIA: suggested diagnostic approach while waiting for evaluation and treatment guidelines. Acta Neurol Scand. 2022 May;145(5):641\u20136.","DOI":"10.1111\/ane.13590"},{"key":"3155_CR43","doi-asserted-by":"publisher","unstructured":"Ntaios G, Weng SF, Perlepe K, et al. Data-driven machine-learning analysis of potential embolic sources in embolic stroke of undetermined source. Eur J Neurol. 2021 Jan;28(1):192\u2013201. https:\/\/doi.org\/10.1111\/ene.14524.","DOI":"10.1111\/ene.14524"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03155-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03155-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03155-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T01:03:32Z","timestamp":1680138212000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03155-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3155"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03155-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"14 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An error was found in the article title. The article has been updated to rectify the errors.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed according to Helsinki Declaration and approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK 2013\/2371) and local ethics committees in Denmark and Sweden. Patients\u00b4 data were collected through the European Cerebrovascular Research Infrastructure (ECRI) and stored in the Services for Sensitive Data (TSD) at the University of Oslo. Written informed consent was obtained from all participants. Study is registered at ClinicalTrials.gov, Identifier: NCT02937077, (18\/10\/2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Concent for publication"}},{"value":"DA has received honoraria and consultation fees from Actelion, Amgen, AstraZeneca, BMS\/Pfizer, Bayer, Boehringer-Ingelheim, MSD, Novartis, Roche Diagnostics, Sanofi, Takeda, and Vifor Pharma; and research funding (to the institution) from BMS\/Pfizer, Bayer, Roche Diagnostics and Medtronic. AHA has received travel support and honoraria for advice or lecturing from Allergan, Bayer, BMS, Boehringer Ingelheim, Novartis, Roche, Sanofi-Genzyme and Teva; research grant from Boehringer Ingelheim and partial financial support from Medtronic and BMS for operating costs in ongoing clinical studies. ATL and BRT have received travel funding from Medtronic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}